Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
McKesson
Johnson and Johnson
Harvard Business School
Moodys

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,316,997

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,316,997 protect, and when does it expire?

Patent 7,316,997 protects EGRIFTA and is included in one NDA.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 7,316,997
Title:GH secretagogues and uses thereof
Abstract:The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
Inventor(s): Abribat; Thierry (St-Foy-les-Lyon, FR), De Villers; Andre (Outremont, CA), Allas; Soraya (Iles Des Soeurs, CA), Gravel; Denis (Saint-Lambert, CA), Chapdelaine; Alcide (Iles Des Soeurs, CA)
Assignee: Theratechnologies Inc. (Ville Saint-Laurent, CA)
Application Number:10/969,463
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,316,997

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes   Start Trial   Start Trial REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY   Start Trial
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes   Start Trial   Start Trial REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
McKesson
Johnson and Johnson
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.